Federal contract award
75N93018C00024
IGF::OT::IGF - "ADVANCED DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES".
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $5.8M |
| Current contract value | $5.8M |
| Potential contract value / ceiling | $18.0M |
| Start date | Sep 20, 2018 |
| Current end date | Aug 14, 2023 |
| Potential end date | Aug 14, 2023 |
| Latest award activity | Sep 23, 2025 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 23, 2025 | P00007 | $-535.7K | TO ADVANCE THE NOVEL H7-ADVAX PANDEMIC VACCINE CANDIDATES THROUGH TO PHASE 1 CLINICAL TRIALS THROUGH DELIVERY TO THE GOVERNMENT OF: PRELIMINARY DATA REGARDING ADJUVANT FOR FORMULATIONS (BASE REQUIREMENT/CLIN 001); MANUFACTURED PRODUCT (RELEASE) FOR S |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.